Insys MDL Group Slams Del. Ch. 11 Doc As Fatally Flawed

By Jeff Montgomery · November 1, 2019, 7:53 PM EDT

Opioid multidistrict litigation claimholders branded Insys Therapeutics' Delaware Chapter 11 disclosure statement as "unapprovable" late Friday, in an objection that described the document as an unsupportable and "fatally misleading" effort to...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login